Mohammed Hamad Al-Thani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mohammed Hamad Al-Thani has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
- Hamad Eid Al-Romaihi
Ministry of Public Health, Doha, Qatar
24 shared publications - Elmoubasher Farag
Department of Health Protection and Communicable Diseases, Ministry of Public Health, Doha, Qatar
14 shared publications - Abdullatif Al-Khal
Hamad Medical Corporation, Doha, Qatar
11 shared publications - Anvar Hassan Kaleeckal
Hamad Medical Corporation, Doha, Qatar
11 shared publications - Hiam Chemaitelly
Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Doha, Qatar
11 shared publications - Laith Jamal Abu Raddad
Infectious Disease Epidemiology Group, Weill Cornell Medicine - Qatar, Cornell University, Doha, Qatar
11 shared publications
Latest Publications
- Open Access
Prevalence of syphilis infection among migrant workers in Qatar: a nationwide cross-sectional survey
Objectives: Scant data are available on syphilis infection within migrant populations worldwide and in the population of the Middle East and North Africa region. This study investigated the prevalence of both lifetime and recent syphilis infections among migrant craft and manual workers (MCMWs) in Qatar, a diverse demographic representing 60% of the country’s population. Methods: Sera specimens collected during a nationwide cross-sectional survey of SARS-CoV-2 seroprevalence among the MCMW population, conducted between 26 July and 9 September 2020, were analysed. Treponema pallidum antibodies were detected using the Mindray CL-900i Chemiluminescence Immunoassay Analyzer. To differentiate recent infections, rapid plasma reagin (RPR) testing was performed, with an RPR titre of ≥1:8 considered indicative of recent infection. Logistic regression analyses were employed to identify factors associated with lifetime syphilis infection. Sampling weights were incorporated into all statistical analyses to obtain population-level estimates. Results: T. pallidum antibodies were identified in 38 of the 2528 tested sera specimens. Prevalence of lifetime infection was estimated at 1.3% (95% CI 0.9% to 1.8%). Among the 38 treponemal-positive specimens, 15 were reactive by RPR, with three having titres ≥1:8, indicating recent infection. Prevalence of recent infection was estimated at 0.09% (95% CI 0.01 to 0.3%). Among treponemal-positive MCMWs, the estimated proportion with recent infection was 8.1% (95% CI: 1.7 to 21.4%). The adjusted OR for lifetime infection increased with age, reaching 8.68 (95% CI 2.58 to 29.23) among those aged ≥60 years compared with those ≤29 years of age. Differences in prevalence were observed by nationality and occupation, but no differences were found by educational attainment or geographic location. Conclusions: Syphilis prevalence among MCMWs in Qatar is consistent with global levels, highlighting a disease burden with implications for health and social well-being. These findings underscore the need for programmes addressing both sexually transmitted infections and the broader sexual health needs of this population.
Open AccessPrevalence of syphilis infection among migrant workers in Qatar: a nationwide cross-sectional survey
Objectives: Scant data are available on syphilis infection within migrant populations worldwide and in the population of the Middle East and North Africa region. This study investigated the prevalence of both lifetime and recent syphilis infections among migrant craft and manual workers (MCMWs) in Qatar, a diverse demographic representing 60% of the country’s population. Methods: Sera specimens collected during a nationwide cross-sectional survey of SARS-CoV-2 seroprevalence among the MCMW population, conducted between 26 July and 9 September 2020, were analysed. Treponema pallidum antibodies were detected using the Mindray CL-900i Chemiluminescence Immunoassay Analyzer. To differentiate recent infections, rapid plasma reagin (RPR) testing was performed, with an RPR titre of ≥1:8 considered indicative of recent infection. Logistic regression analyses were employed to identify factors associated with lifetime syphilis infection. Sampling weights were incorporated into all statistical analyses to obtain population-level estimates. Results: T. pallidum antibodies were identified in 38 of the 2528 tested sera specimens. Prevalence of lifetime infection was estimated at 1.3% (95% CI 0.9% to 1.8%). Among the 38 treponemal-positive specimens, 15 were reactive by RPR, with three having titres ≥1:8, indicating recent infection. Prevalence of recent infection was estimated at 0.09% (95% CI 0.01 to 0.3%). Among treponemal-positive MCMWs, the estimated proportion with recent infection was 8.1% (95% CI: 1.7 to 21.4%). The adjusted OR for lifetime infection increased with age, reaching 8.68 (95% CI 2.58 to 29.23) among those aged ≥60 years compared with those ≤29 years of age. Differences in prevalence were observed by nationality and occupation, but no differences were found by educational attainment or geographic location. Conclusions: Syphilis prevalence among MCMWs in Qatar is consistent with global levels, highlighting a disease burden with implications for health and social well-being. These findings underscore the need for programmes addressing both sexually transmitted infections and the broader sexual health needs of this population.
- Open Access
- 9 April 2024
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 31 (4)
Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
Evidence at the level of neutralizing antibodies suggests that the SARS-CoV-2 JN.1 variant demonstrates increased immune evasion compared to its parent lineage BA.2.86 and to recently circulating variants, such as XBB.1.5 and EG.5.1. 1 JN.1 has also exhibited a growth advantage over other variants and triggered large SARS-CoV-2 waves in various countries, 2 prompting the World Health Organization to classify it as a variant of interest on 19 December 2023. 2 We estimated the effectiveness of natural infection in preventing reinfection with JN.1 during a large JN.1 wave in Qatar using the test-negative case-control study design. 3, 4
- 9 April 2024
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 31 (4)
Open AccessProtection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
Evidence at the level of neutralizing antibodies suggests that the SARS-CoV-2 JN.1 variant demonstrates increased immune evasion compared to its parent lineage BA.2.86 and to recently circulating variants, such as XBB.1.5 and EG.5.1. 1 JN.1 has also exhibited a growth advantage over other variants and triggered large SARS-CoV-2 waves in various countries, 2 prompting the World Health Organization to classify it as a variant of interest on 19 December 2023. 2 We estimated the effectiveness of natural infection in preventing reinfection with JN.1 during a large JN.1 wave in Qatar using the test-negative case-control study design. 3, 4
- Open Access
- 7 December 2023
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (6) , 883-897
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design
The COVID-19 pandemic has highlighted the need to use infection testing databases to rapidly estimate effectiveness of prior infection in preventing reinfection ($P{E}_S$) by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Mathematical modeling was used to demonstrate a theoretical foundation for applicability of the test-negative, case–control study design to derive $P{E}_S$. Apart from the very early phase of an epidemic, the difference between the test-negative estimate for $P{E}_S$ and true value of $P{E}_S$ was minimal and became negligible as the epidemic progressed. The test-negative design provided robust estimation of $P{E}_S$ and its waning. Assuming that only 25% of prior infections are documented, misclassification of prior infection status underestimated $P{E}_S$, but the underestimate was considerable only when > 50% of the population was ever infected. Misclassification of latent infection, misclassification of current active infection, and scale-up of vaccination all resulted in negligible bias in estimated $P{E}_S$. The test-negative design was applied to national-level testing data in Qatar to estimate $P{E}_S$ for SARS-CoV-2. $P{E}_S$ against SARS-CoV-2 Alpha and Beta variants was estimated at 97.0% (95% CI, 93.6-98.6) and 85.5% (95% CI, 82.4-88.1), respectively. These estimates were validated using a cohort study design. The test-negative design offers a feasible, robust method to estimate protection from prior infection in preventing reinfection.- 7 December 2023
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (6) , 883-897
Open AccessEstimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design
The COVID-19 pandemic has highlighted the need to use infection testing databases to rapidly estimate effectiveness of prior infection in preventing reinfection ($P{E}_S$) by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Mathematical modeling was used to demonstrate a theoretical foundation for applicability of the test-negative, case–control study design to derive $P{E}_S$. Apart from the very early phase of an epidemic, the difference between the test-negative estimate for $P{E}_S$ and true value of $P{E}_S$ was minimal and became negligible as the epidemic progressed. The test-negative design provided robust estimation of $P{E}_S$ and its waning. Assuming that only 25% of prior infections are documented, misclassification of prior infection status underestimated $P{E}_S$, but the underestimate was considerable only when > 50% of the population was ever infected. Misclassification of latent infection, misclassification of current active infection, and scale-up of vaccination all resulted in negligible bias in estimated $P{E}_S$. The test-negative design was applied to national-level testing data in Qatar to estimate $P{E}_S$ for SARS-CoV-2. $P{E}_S$ against SARS-CoV-2 Alpha and Beta variants was estimated at 97.0% (95% CI, 93.6-98.6) and 85.5% (95% CI, 82.4-88.1), respectively. These estimates were validated using a cohort study design. The test-negative design offers a feasible, robust method to estimate protection from prior infection in preventing reinfection. - Open Access
- 1 July 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (5)
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains. 1 We estimated this vaccine’s effectiveness against SARS-CoV-2 infection.
- 1 July 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (5)
Open AccessBivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains. 1 We estimated this vaccine’s effectiveness against SARS-CoV-2 infection.
- Open Access
Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar
There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan–Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibody titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13,720.9 AU/mL (IQR 6426.5 to 30,185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/mL; IQR, 3757.9 to 16,577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7–5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2–4.5 months) and 7.63 months (IQR, 6.3–8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. This evidence on anti-S IgG antibody titers should be considered for informing decisions on the durability of the neutralizing activity and thus protection against infection after the full course of primary vaccination in individuals receiving different type (mRNA verus non-mRNA) vaccines and those with natural infection.
Open AccessDynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar
There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan–Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibody titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13,720.9 AU/mL (IQR 6426.5 to 30,185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/mL; IQR, 3757.9 to 16,577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7–5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2–4.5 months) and 7.63 months (IQR, 6.3–8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. This evidence on anti-S IgG antibody titers should be considered for informing decisions on the durability of the neutralizing activity and thus protection against infection after the full course of primary vaccination in individuals receiving different type (mRNA verus non-mRNA) vaccines and those with natural infection.
- Open Access
- 20 February 2023
- Published by MDPI AG in Microbiology Research
- Vol. 14 (1) , 289-296
Association between Multimorbidity and COVID-19 Mortality in Qatar: A Cross-Sectional Study
This study assessed the association between multimorbidity and mortality from COVID-19 in the Middle East and North Africa region, where such data are scarce. We conducted a cross-sectional study using data of all cases with COVID-19 reported to the Ministry of Public Health of Qatar from March to September 2020. Data on pre-existing comorbidities were collected using a questionnaire and multimorbidity was defined as having at least two comorbidities. Proportions of deaths were compared by comorbidity and multimorbidity status and multivariable logistic regression analyses were carried out. A total of 92,426 participants with a mean age of 37.0 years (SD 11.0) were included. Mortality due to COVID-19 was associated with gastrointestinal diseases (aOR 3.1, 95% CI 1.16–8.30), respiratory diseases (aOR 2.9, 95% CI 1.57–5.26), neurological diseases (aOR 2.6, 95% CI 1.19–5.54), diabetes (aOR 1.8, 95% CI 1.24–2.61), and CVD (aOR 1.5, 95% CI 1.03–2.22). COVID-19 mortality was strongly associated with increasing multimorbidity; one comorbidity (aOR 2.0, 95% CI 1.28–3.12), two comorbidities (aOR 2.8, 95% CI 1.79–4.38), three comorbidities (aOR 6.0, 95% 3.34–10.86) and four or more comorbidities (aOR 4.15, 95% 1.3–12.88). This study demonstrates a strong association between COVID-19 mortality and multimorbidity in Qatar.
- 20 February 2023
- Published by MDPI AG in Microbiology Research
- Vol. 14 (1) , 289-296
Open AccessAssociation between Multimorbidity and COVID-19 Mortality in Qatar: A Cross-Sectional Study
This study assessed the association between multimorbidity and mortality from COVID-19 in the Middle East and North Africa region, where such data are scarce. We conducted a cross-sectional study using data of all cases with COVID-19 reported to the Ministry of Public Health of Qatar from March to September 2020. Data on pre-existing comorbidities were collected using a questionnaire and multimorbidity was defined as having at least two comorbidities. Proportions of deaths were compared by comorbidity and multimorbidity status and multivariable logistic regression analyses were carried out. A total of 92,426 participants with a mean age of 37.0 years (SD 11.0) were included. Mortality due to COVID-19 was associated with gastrointestinal diseases (aOR 3.1, 95% CI 1.16–8.30), respiratory diseases (aOR 2.9, 95% CI 1.57–5.26), neurological diseases (aOR 2.6, 95% CI 1.19–5.54), diabetes (aOR 1.8, 95% CI 1.24–2.61), and CVD (aOR 1.5, 95% CI 1.03–2.22). COVID-19 mortality was strongly associated with increasing multimorbidity; one comorbidity (aOR 2.0, 95% CI 1.28–3.12), two comorbidities (aOR 2.8, 95% CI 1.79–4.38), three comorbidities (aOR 6.0, 95% 3.34–10.86) and four or more comorbidities (aOR 4.15, 95% 1.3–12.88). This study demonstrates a strong association between COVID-19 mortality and multimorbidity in Qatar.
- Open Access
- 26 December 2022
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 16 (2) , 250-256
Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
- 26 December 2022
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 16 (2) , 250-256
Open AccessEffectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
- Open Access
- 8 December 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (24) , 16509
Feasibility and Acceptability of a Telephone-Based Smoking Cessation Intervention for Qatari Residents
The steady increase in smoking rates has led to a call for wide-reaching and scalable interventions for smoking cessation in Qatar. This study examined the feasibility and acceptability of an evidence-based smoking cessation program delivered by telephone for Qatari residents. A total of 248 participants were recruited through primary care centers and received five weekly scheduled proactive behavioral counseling calls from personnel trained in tobacco cessation and navigation to obtain cessation pharmacotherapy from clinics. Outcomes were assessed at end of treatment (EOT), and 1- and-3-month follow up. The Mann–Whitney test was used to compare the average number of participants recruited per month pre- and post-COVID. We recruited 16 participants/month, the majority (85.5%) attended at least one counselling session, and 95.4% used some of pharmacotherapy. Retention rates were 70% at EOT, 64.4% and 71.7% at 1- and 3-month follow up, respectively; 86% reported being ‘extremely satisfied’ by the program. Our ITT 7-day point prevalence abstinence was 41.6% at EOT, 38.4% and 39.3% at 1-and 3-month, respectively. The average number of participants recruited per month was significantly higher for pre vs. post-COVID (18.9 vs. 10.0, p-value = 0.02). Average number of participants retained at EOT per recruitment month showed a slight decrease from 8.6 pre- to 8.2 post-COVID; average number who quit smoking at EOT per recruitment month also showed a decrease from 6 to 4.6. The study results indicated that our telephone-based intervention is feasible and acceptable in this population and presents a new treatment model which can be easily disseminated to a broad population of Qatari smokers.
- 8 December 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (24) , 16509
Open AccessFeasibility and Acceptability of a Telephone-Based Smoking Cessation Intervention for Qatari Residents
The steady increase in smoking rates has led to a call for wide-reaching and scalable interventions for smoking cessation in Qatar. This study examined the feasibility and acceptability of an evidence-based smoking cessation program delivered by telephone for Qatari residents. A total of 248 participants were recruited through primary care centers and received five weekly scheduled proactive behavioral counseling calls from personnel trained in tobacco cessation and navigation to obtain cessation pharmacotherapy from clinics. Outcomes were assessed at end of treatment (EOT), and 1- and-3-month follow up. The Mann–Whitney test was used to compare the average number of participants recruited per month pre- and post-COVID. We recruited 16 participants/month, the majority (85.5%) attended at least one counselling session, and 95.4% used some of pharmacotherapy. Retention rates were 70% at EOT, 64.4% and 71.7% at 1- and 3-month follow up, respectively; 86% reported being ‘extremely satisfied’ by the program. Our ITT 7-day point prevalence abstinence was 41.6% at EOT, 38.4% and 39.3% at 1-and 3-month, respectively. The average number of participants recruited per month was significantly higher for pre vs. post-COVID (18.9 vs. 10.0, p-value = 0.02). Average number of participants retained at EOT per recruitment month showed a slight decrease from 8.6 pre- to 8.2 post-COVID; average number who quit smoking at EOT per recruitment month also showed a decrease from 6 to 4.6. The study results indicated that our telephone-based intervention is feasible and acceptable in this population and presents a new treatment model which can be easily disseminated to a broad population of Qatari smokers.
- Open Access
Rabies Virus Populations in Humans and Mice Show Minor Inter-Host Variability within Various Central Nervous System Regions and Peripheral Tissues
Rabies virus (RABV) has a broad host range and infects multiple cell types throughout the infection cycle. Next-generation sequencing (NGS) and minor variant analysis are powerful tools for studying virus populations within specific hosts and tissues, leading to novel insights into the mechanisms of host-switching and key factors for infecting specific cell types. In this study we investigated RABV populations and minor variants in both original (non-passaged) samples and in vitro-passaged isolates of various CNS regions (hippocampus, medulla oblongata and spinal cord) of a fatal human rabies case, and of multiple CNS and non-CNS tissues of experimentally infected mice. No differences in virus populations were detected between the human CNS regions, and only one non-synonymous single nucleotide polymorphism (SNP) was detected in the fifth in vitro passage of virus isolated from the spinal cord. However, the appearance of this SNP shows the importance of sequencing newly passaged virus stocks before further use. Similarly, we did not detect apparent differences in virus populations isolated from different CNS and non-CNS tissues of experimentally infected mice. Sequencing of viruses obtained from pharyngeal swab and salivary gland proved difficult, and we propose methods for improving sampling.
Open AccessRabies Virus Populations in Humans and Mice Show Minor Inter-Host Variability within Various Central Nervous System Regions and Peripheral Tissues
Rabies virus (RABV) has a broad host range and infects multiple cell types throughout the infection cycle. Next-generation sequencing (NGS) and minor variant analysis are powerful tools for studying virus populations within specific hosts and tissues, leading to novel insights into the mechanisms of host-switching and key factors for infecting specific cell types. In this study we investigated RABV populations and minor variants in both original (non-passaged) samples and in vitro-passaged isolates of various CNS regions (hippocampus, medulla oblongata and spinal cord) of a fatal human rabies case, and of multiple CNS and non-CNS tissues of experimentally infected mice. No differences in virus populations were detected between the human CNS regions, and only one non-synonymous single nucleotide polymorphism (SNP) was detected in the fifth in vitro passage of virus isolated from the spinal cord. However, the appearance of this SNP shows the importance of sequencing newly passaged virus stocks before further use. Similarly, we did not detect apparent differences in virus populations isolated from different CNS and non-CNS tissues of experimentally infected mice. Sequencing of viruses obtained from pharyngeal swab and salivary gland proved difficult, and we propose methods for improving sampling.
- Open Access
- 25 October 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 7 (11) , 329
Dengue Epidemiology in Qatar from 2013–2021: A Retrospective Study
(1) Background: Qatar does not have any indigenous cases of dengue; however, the influx of immigrants from dengue endemic countries, the environment, and climate suitability for Aedes vector mosquitoes suggest a potential risk for local transmission. In this study, we investigated various demographic factors to determine the epidemiological features of dengue in Qatar. (2) Methods: In the present retrospective study, we reviewed dengue notification data received at the national surveillance system, Ministry of Public Health, Qatar, between January 2013, and December 2021, and we analyzed the incidence of the dengue disease burden to identify factors that could contribute to the dissemination of the disease in Qatar. (3) Results: A total of 166 dengue fever seropositive cases were recorded during the study period in Qatar. The mean incidence was estimated to be 0.7/100,000 population, which increased from 0.7/100,000 in 2013 to 1.5/100,000 in 2019. The majority of the cases were male, between 20–50 years of age and notified during the hot months (June-September). Most of the patients had fever without hemorrhagic manifestations. There were no dengue related deaths during 2013–2021. (4) Conclusion: Dengue fever occurred more frequently among men than women, and its incidence is low among Qatari nationals. The presence of the most efficient vector, Aedes aegypti, in Qatar, if confirmed, poses a risk of local outbreaks. Therefore, regular vector surveillance is needed to assess the distribution, biting habits and abundance of vector mosquito species and the risk for mosquito-borne diseases.
- 25 October 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 7 (11) , 329
Open AccessDengue Epidemiology in Qatar from 2013–2021: A Retrospective Study
(1) Background: Qatar does not have any indigenous cases of dengue; however, the influx of immigrants from dengue endemic countries, the environment, and climate suitability for Aedes vector mosquitoes suggest a potential risk for local transmission. In this study, we investigated various demographic factors to determine the epidemiological features of dengue in Qatar. (2) Methods: In the present retrospective study, we reviewed dengue notification data received at the national surveillance system, Ministry of Public Health, Qatar, between January 2013, and December 2021, and we analyzed the incidence of the dengue disease burden to identify factors that could contribute to the dissemination of the disease in Qatar. (3) Results: A total of 166 dengue fever seropositive cases were recorded during the study period in Qatar. The mean incidence was estimated to be 0.7/100,000 population, which increased from 0.7/100,000 in 2013 to 1.5/100,000 in 2019. The majority of the cases were male, between 20–50 years of age and notified during the hot months (June-September). Most of the patients had fever without hemorrhagic manifestations. There were no dengue related deaths during 2013–2021. (4) Conclusion: Dengue fever occurred more frequently among men than women, and its incidence is low among Qatari nationals. The presence of the most efficient vector, Aedes aegypti, in Qatar, if confirmed, poses a risk of local outbreaks. Therefore, regular vector surveillance is needed to assess the distribution, biting habits and abundance of vector mosquito species and the risk for mosquito-borne diseases.